{"classes":[{"categories":[{"measurements":[{"comment":"The median overall survival was not reached, and the lower and upper limits of the 95% confidence interval were not available.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Survival time is defined as the time from registration to death due to any cause. The distribution of survival time will be estimated using the method of Kaplan-Meier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive SMAC mimetic LCL161 (1200 mg) PO QD on days 1, 8, 15, and 22. Patients lacking a minor response by end of course 2 or partial response by end of course 4 may also receive cyclophosphamide (500 mg) PO QD on days 1, 8, 15, and 22 at the discretion of the treating physician. Patients taking cyclophosphamide with less than a 25% interval reduction in paraprotein receive SMAC mimetic LCL161 on days 2, 9, 16, and 23. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Treatment (SMAC Mimetic LCL161 and Cyclophosphamide)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From registration to death due to any cause, assessed up to 1 year","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}